The 4th TIGIT Axis Therapies Digital Summit is dedicated to deciphering therapeutic targets in the TIGIT axis to validate biomarkers & defining desirable checkpoint combinations.
The 4th TIGIT Axis Therapies Digital Summit covers topics such as:
- Leverage biomarkers to identify patient responders, monitor therapies and delve deeper into drug MoA with Genentech & Case Western Reserve University
- Decipher the TIGIT axis at a mechanistic level and optimize preclinical models with Dana-Farber Cancer Institute, University Hospital Bonn & University of Central Florida
- Optimize Fc gamma receptor engagement with iTeos Therapeutics, and discuss dosing considerations for TIGIT combinations with Gilead Sciences
- Explore the next era of TIGIT axis targeted therapies in preclinical development with Shattuck Labs, Nectin Therapeutics, Compugen & Mereo Biopharma
The 4th TIGIT Axis Therapies Digital Summit brings together:
- Case Western Reserve University
- Aurigene Discovery Technologies
- Compugen
- Coherus Biosciences
- Genentech
- Dana-Farber Cancer Institute
- GlaxoSmithKline
- Gilead Sciences
- ITeos Therapeutics
- Graphite Bio
- Mereo Biopharma
- Nectin Therapeutics
- Shattuck Labs
- Mayo Clinic
- University of Zurich
- Orion Corporation
- University of Central Florida
- University Hospital Bonn
- And many more!
- University Medical Center Hamburg-Eppendorf